Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125121) titled 'A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Vericiguat in Patients with Hypertrophic Cardiomyopathy and Heart Failure' on May 21.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Fuwai Hospital, Chinese Academy of Medical Sciences
Condition:
Hypertrophic cardiomyopathy
Intervention:
Experimental group:Administer vericiguat. The recommended starting dose is 5 mg/day. During the treatment period, dose titration should be performed at each follow-up visit based on blood pressure, symptoms, adverse reactions, and other factors:
- If SBP >...